Posted on 06/08/2009 in Veterinary Supplier News Fort Dodge Animal Health is likely to have some of its assets purchased by Boehringer Ingelheim, it has been reported.
Citing "sources familiar with the situation", Reuters said that the company is the "front-runner" to buy the assets that are being divested by Wyeth.
The news agency explained that Wyeth must eliminate part of its Fort Dodge livestock and veterinary animal health business in order to gain approval for its merger with Pfizer.
Reuters reported: "Wyeth is not selling its entire Fort Dodge business, just certain assets within the unit that are valued at roughly $400 million (235 million pounds) to $500 million, the sources said."
The Fort Dodge Animal Health business makes a variety of different products, including ProHeart6, ProMeris and the Duramune range of vaccines.
At their annual meeting, the 2009 edition of which was held last month, Wyeth's stockholders "overwhelmingly" approved the adoption of its merger agreement with Pfizer.Other news stories from 06/08/2009
Read more in the Zenopa News Archive
How this news is generated
|
